Catalyst Biosciences Inc., of South San Francisco, said the Korean Ministry of Food and Drug Safety approved the IND for CB 2679d/ISU304, in hemophilia. CB 2679d/ISU304 is described as a highly potent next-generation coagulation factor IX variant, and it has demonstrated the potential to normalize human factor IX levels with a daily subcutaneous injection in preclinical studies.